Clinical bottom line
Venetoclax, a BCL-2 inhibitor, has emerged as a promising treatment for Chronic Lymphocytic Leukemia (CLL), particularly when used in combination with other agents. Recent studies highlight its effectiveness in achieving deep remissions and improving progression-free survival (PFS) in both treatment-naïve and relapsed/refractory CLL patients. However, the optimal combination and sequencing with other therapies remain under investigation.
What the evidence shows
Recent clinical trials have demonstrated the efficacy of venetoclax in combination with other agents, such as rituximab and obinutuzumab. A pivotal study, the MURANO trial, showed that venetoclax combined with rituximab significantly improved PFS compared to bendamustine plus rituximab in relapsed/refractory CLL patients (Seymour JF, et al. N Engl J Med 2018;378:1107-1120. PMID: 29261948). This combination has become a standard of care for this patient population.
In treatment-naïve patients, the CLL14 trial demonstrated that venetoclax combined with obinutuzumab resulted in superior PFS compared to chlorambucil plus obinutuzumab (Fischer K, et al. N Engl J Med 2019;380:2225-2236. PMID: 31166681). This combination is now recommended for first-line treatment in older patients or those with comorbidities.
Additionally, a recent systematic review and meta-analysis confirmed the efficacy of venetoclax combinations in achieving high rates of minimal residual disease (MRD) negativity, which is associated with improved long-term outcomes (Al-Sawaf O, et al. Blood 2020;135:1421-1430. PMID: 31932895).
Caveats and uncertainty
While venetoclax combinations have shown promise, several uncertainties remain. The risk of tumor lysis syndrome (TLS) is a significant concern, requiring careful monitoring and prophylaxis during treatment initiation. Furthermore, the long-term safety profile of venetoclax, particularly in combination regimens, is still being evaluated.
There is also ongoing debate about the optimal duration of venetoclax therapy. While fixed-duration regimens have been shown to be effective, the potential benefits of continuous therapy versus fixed-duration treatment are still under investigation.
How this may change practice
The integration of venetoclax into CLL treatment regimens represents a significant advancement, offering an effective option for both treatment-naïve and relapsed/refractory patients. Clinicians may increasingly consider venetoclax combinations as a first-line treatment, particularly for patients who are older or have comorbidities.
The ability of venetoclax to achieve MRD negativity may also influence treatment goals and monitoring strategies, with a focus on achieving deep remissions. However, careful patient selection and monitoring for TLS are essential to maximize the benefits of venetoclax-based therapies.